Expert Review of Pharmacoeconomics & Outcomes Research
Volume 23, 2023 - Issue 2
Original Research
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A
Michael Bullanoa U.S Medical Office, Health Economics and Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-9961-4576View further author information
https://orcid.org/0000-0002-9961-4576View further author information, Christina Coolb Precision Value and Health, New York, CA, USAhttps://orcid.org/0000-0003-0086-3474View further author information
https://orcid.org/0000-0003-0086-3474View further author information, Bob G. Schultza U.S Medical Office, Health Economics and Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USAhttps://orcid.org/0000-0002-7023-8378View further author information
https://orcid.org/0000-0002-7023-8378View further author information, , Naomi Sacksb Precision Value and Health, New York, CA, USAhttps://orcid.org/0000-0003-0038-4385View further author information
https://orcid.org/0000-0003-0038-4385View further author information, , & Katharine Battb Precision Value and Health, New York, CA, USA;c Department of Internal Medicine, Division of Hematology/Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USAhttps://orcid.org/0000-0003-3672-8741View further author information
https://orcid.org/0000-0003-3672-8741View further author information show all